<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65518">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998438</url>
  </required_header>
  <id_info>
    <org_study_id>2011GWH1</org_study_id>
    <nct_id>NCT01998438</nct_id>
  </id_info>
  <brief_title>Prospective Trial of Tranexamic Acid in Cardiac Surgery</brief_title>
  <official_title>A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hongwen Ji</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Institute &amp; Fuwai Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease
      perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is
      still unknown. We use three different doses to find which is the optimum dose of tranexamic
      acid in cardiopulmonary bypass cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>postoperative blood loss</measure>
    <time_frame>on the 7th day postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants needs allogenic transfusion</measure>
    <time_frame>on the 7th day postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>rate of reexploration for bleeding</measure>
    <time_frame>on the 7th day postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">810</enrollment>
  <condition>C.Surgical Procedure; Cardiac</condition>
  <arm_group>
    <arm_group_label>small dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>large dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>small dose</arm_group_label>
    <arm_group_label>medium dose</arm_group_label>
    <arm_group_label>large dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Noncyanotic congenital heart disease patients requiring cardiac surgeries under
             cardiopulmonary bypass

          -  Rheumatic or recessive valvular disease patients requiring valvular repair or
             replacement under cardiopulmonary bypass

          -  Coronary artery disease patients requiring coronary artery bypass graft under
             cardiopulmonary bypass

        Exclusion Criteria:

          -  Non-primary and emergency cardiac surgery

          -  Disorder in coagulation function before surgery

          -  Anemia before surgery

          -  Definite liver and renal dysfunction

          -  History of stroke

          -  Pregnancy and lactation

          -  Disabled in spirit or law

          -  Fatal conditions such as cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongwen Ji, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haisong Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongwen Ji, MD</last_name>
    <phone>86-10-88398185</phone>
    <email>jihongwen@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haisong Lu</last_name>
    <phone>86-10-88398082</phone>
    <email>luhaisong@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongwen Ji, MD</last_name>
      <phone>86-10-88398185</phone>
      <email>jihongwen@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Haisong Lu</last_name>
      <phone>86-10-88398082</phone>
      <email>luhaisong@aliyun.com</email>
    </contact_backup>
    <investigator>
      <last_name>Haisong Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 24, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union M</investigator_affiliation>
    <investigator_full_name>Hongwen Ji</investigator_full_name>
    <investigator_title>professor of medicine</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
